SCHEMBL13611475

SCHEMBL13611475

CNC(=S)N/N=C/c1ccc(-c2cccc(Cl)c2)o1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.71
KDM4E B2RXH2 9/20 0.71
PKM P14618 3/20 0.71
NPC1 O15118 3/20 0.71
RAB9A P51151 2/20 0.71
HPGD P15428 5/20 0.68
LMNA P02545 6/20 0.62
KMT2A Q03164 6/20 0.62
MEN1 O00255 5/20 0.62
POLB P06746 3/20 0.62
TDP1 Q9NUW8 2/20 0.62
HSP90AA1 P07900 2/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
APEX1 P27695 1/20 0.60
ALDH1A1 P00352 6/20 0.58
ALOX12 P18054 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GAA P10253 3/20 0.58
MAPK1 P28482 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13611595 0.87 ALDH1A1 (0.75) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL4455965 0.87 ALDH1A1 (0.75) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL4328166 0.85 MAPT (0.79) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL4328162 0.85 MAPT (0.79) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL13611615 0.85 MAPT (0.72) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL4462860 0.85 MAPT (0.72) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL13611637 0.85 MAPT (0.75) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL4459314 0.85 MAPT (0.75) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL13887126 0.84 KMT2A (0.74) MAPTKDM4EPKMNPC1RAB9A
SCHEMBL4453439 0.84 KMT2A (0.74) MAPTKDM4EPKMNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885KDM4E 3010/4885PKM 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.